MPLT 8-K: SEC filing
MapLight Therapeutics
Filed with the SEC on · accession 0001193125-26-462061
MPLT filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -0.7% by the first close after the filing.
Summary of the filing
MapLight Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, and updated its corporate presentation for investor meetings.
Key details
How MPLT stock reacted
Close before
$7.25
Nov 13, 2026
First close after
-0.69%
$7.20
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MPLT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MPLT?
Click hereFrequently asked questions
What did MPLT file with the SEC on Nov 16, 2026?
MPLT filed a 8-K (SEC filing). MapLight Therapeutics issued a press release announcing its financial results for the third quarter ended September 30, 2026, and updated its corporate presentation for investor meetings.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
How did MPLT stock react to this filing?
MPLT closed at $7.25 before the filing and $7.20 on Nov 16, 2026 (-0.69%).
Other MPLT SEC filings
- 10-Q · SEC filingNov 16, 2026
- EFFECT · SEC filingSep 23, 2026
- 424B3 · Secondary offeringSep 23, 2026
- S-1 · SEC filingSep 18, 2026
- S-1 · SEC filingSep 9, 2026
- SCHEDULE 13G · SEC filingAug 20, 2026
- SCHEDULE 13D/A · SEC filingAug 18, 2026
- 10-Q · SEC filingAug 13, 2026
- 8-K · Secondary offeringAug 13, 2026
- 8-K · Fda approvalJul 27, 2026
Get alerts when MPLT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days